Phase II RCT of senolytics showed safety and feasibility in older adults with mild cognitive impairment or early Alzheimer's disease
A Phase II randomized controlled trial evaluated senolytics in older adults with amnestic mild cognitive impairment or early-stage Alzheimer's disease who were tau PET positive. The study assessed safety, feasibility, and efficacy of the intervention. Specific efficacy results, sample size, and effect sizes were not reported in the available material.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 1, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- —
- Effect size
- —
- Significance
- Not reported
- Journal
- Washington University School of Medicine
- Published
- Apr 1, 2026
Sources
Primary source
- Washington University School of Medicine ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.